Climb Bio, Inc.
CLYM
Get informed when a big investor buys or sells
+ FollowMarket Cap$342.68M
Close$
Share Statistics
| Market cap | $342.68 Million |
|---|---|
| Enterprise Value | $299.88 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -24.06% |
|---|---|
| Return on Assets | -23.40% |
| Return on Invested Capital | -27.00% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.62 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Eliem Therapeutics Inc
2,021 employees
CEO: Aoife Brennan BCh MMSc Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This tre...